Scholarlink

<p>Although studies suggest that astaxanthin exerts anticancer effects through Wnt/β-catenin pathway, its therapeutic target remains unclear. The deubiquitinase USP39 may be a potential target due to its ability to regulate this pathway in hepatocellular carcinoma (HCC). This study aims to identify the role and underlying mechanism of USP39 in the anti-HCC effects of astaxanthin via Wnt/β-catenin pathway. In vitro, HepG2 and HuH7 cell lines were treated with astaxanthin, and cell proliferation was assessed using CCK-8, colony formation, and EdU assays. Western blot and real-time qPCR were used to analyze the expression of USP39, β-catenin, and Cyclin D1. Co-immunoprecipitation and ubiquitination assays were performed to confirm the interaction between USP39 and β-catenin. In vivo, HuH7 xenografts in nude mice were established to evaluate tumor growth following astaxanthin treatment. Immunohistochemistry and western blot analyses were conducted to examine the expression of USP39, β-catenin, Cyclin D1, and Ki-67 in tumor tissues. Astaxanthin treatment significantly reduced cell viability and colony formation, accompanied by decreased levels of USP39, β-catenin, and Cyclin D1, and increased phosphorylated β-catenin. Astaxanthin-induced USP39 inhibition promoted β-catenin ubiquitination and degradation, thereby blocking Wnt/β-catenin pathway activation. β-catenin overexpression partially rescued the anti-tumor effects of USP39 knockdown. Astaxanthin significantly suppressed tumor growth, inhibited the expression of USP39, β-catenin, and Cyclin D1, and reduced the proportion of Ki-67-positive cells in tumor tissues. Astaxanthin inhibits HCC through USP39-mediated ubiquitination of β-catenin, providing novel insights into its anticancer mechanism. These findings highlight the potential of targeting USP39 for HCC therapy, especially in combination with astaxanthin.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Astaxanthin inhibits hepatocellular carcinoma by targeting USP39-mediated β-catenin stabilization through deubiquitination

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月14日

查看全文
  • Xiaomei Li,
  • Huiyuan Xu,
  • Ruoxi Chen,
  • Xianzhi Huang,
  • Zequan Lin,
  • Shouan Wang,
  • Lihong Han,
  • Jinqiu Li,
  • Lihong Lin,
  • Yamei Qi,
  • Gang Song,
  • Conghua Song

摘要

Although studies suggest that astaxanthin exerts anticancer effects through Wnt/β-catenin pathway, its therapeutic target remains unclear. The deubiquitinase USP39 may be a potential target due to its ability to regulate this pathway in hepatocellular carcinoma (HCC). This study aims to identify the role and underlying mechanism of USP39 in the anti-HCC effects of astaxanthin via Wnt/β-catenin pathway. In vitro, HepG2 and HuH7 cell lines were treated with astaxanthin, and cell proliferation was assessed using CCK-8, colony formation, and EdU assays. Western blot and real-time qPCR were used to analyze the expression of USP39, β-catenin, and Cyclin D1. Co-immunoprecipitation and ubiquitination assays were performed to confirm the interaction between USP39 and β-catenin. In vivo, HuH7 xenografts in nude mice were established to evaluate tumor growth following astaxanthin treatment. Immunohistochemistry and western blot analyses were conducted to examine the expression of USP39, β-catenin, Cyclin D1, and Ki-67 in tumor tissues. Astaxanthin treatment significantly reduced cell viability and colony formation, accompanied by decreased levels of USP39, β-catenin, and Cyclin D1, and increased phosphorylated β-catenin. Astaxanthin-induced USP39 inhibition promoted β-catenin ubiquitination and degradation, thereby blocking Wnt/β-catenin pathway activation. β-catenin overexpression partially rescued the anti-tumor effects of USP39 knockdown. Astaxanthin significantly suppressed tumor growth, inhibited the expression of USP39, β-catenin, and Cyclin D1, and reduced the proportion of Ki-67-positive cells in tumor tissues. Astaxanthin inhibits HCC through USP39-mediated ubiquitination of β-catenin, providing novel insights into its anticancer mechanism. These findings highlight the potential of targeting USP39 for HCC therapy, especially in combination with astaxanthin.